New York, New York, USA, November 17, 2026
SELLAS Life Sciences Group, Inc. has announced positive topline results from its pivotal Phase 3 REGAL clinical trial, reporting that its investigational immunotherapeutic cancer vaccine, galinpepimut-S (GPS), significantly improved overall survival in patients with acute myeloid leukemia (AML). The randomized study met its primary endpoint, demonstrating a statistically significant reduction in the risk of death compared with investigator-selected best available treatment. Patients receiving GPS achieved a median overall survival of 24.0 months, compared with 14.7 months among patients receiving best available treatment. The company reported a 41% reduction in the risk of death, with a hazard ratio of 0.59 and a two-sided p-value of 0.035. The findings represent an important clinical development milestone for SELLAS and support further evaluation of immune-based maintenance treatment for patients with high-risk AML who have limited treatment options after achieving a second or subsequent remission.
Phase 3 REGAL Trial Meets Primary Overall Survival Endpoint
The global, randomized, open-label Phase 3 REGAL trial (NCT04229979) evaluated GPS as maintenance monotherapy in patients with AML who had achieved a second or later complete remission (CR2 or later), or complete remission with insufficient platelet recovery (CRp2 or later), following second- or later-line salvage treatment. The study focused on patients who were ineligible for, or unable to undergo, an allogeneic hematopoietic stem cell transplant. A total of 126 patients were randomized in a 1:1 ratio to receive either GPS or investigator-selected best available treatment (BAT). The control options included observation, hypomethylating agents, venetoclax and low-dose cytarabine, depending on the investigator’s choice. Overall survival, measured from study entry, was the primary endpoint. According to SELLAS, the prespecified analysis was conducted after the trial reached 80 death events, in accordance with its statistical analysis plan. The results showed median overall survival of 24.0 months in the GPS group versus 14.7 months in the BAT group, alongside a hazard ratio of 0.59. The reported p-value of 0.035 indicates that the primary endpoint achieved statistical significance under the trial’s prespecified analysis. These findings suggest that GPS may offer a maintenance treatment option for a particularly challenging AML population in which relapse and limited transplant eligibility can create substantial clinical needs.
GPS Uses WT1-Targeted Immunotherapy to Address Residual Leukemia
Galinpepimut-S (GPS) is an investigational, off-the-shelf immunotherapeutic cancer vaccine designed to stimulate the body’s immune response against cells expressing Wilms’ Tumor 1 (WT1), a protein found in AML and several other hematological malignancies and solid tumors. The vaccine contains four WT1-derived peptides intended to generate a broad immune response across different human leukocyte antigen (HLA) types. Its therapeutic approach is designed to activate both CD4-positive and CD8-positive T cells, which play important roles in coordinating immune activity and identifying abnormal cells. In the AML maintenance setting, the objective is to help the immune system recognize and attack residual leukemia cells that may remain after patients achieve remission. By targeting WT1-expressing cells, GPS is being investigated as a potential strategy to prolong remission and improve survival following salvage therapy. The candidate was licensed to SELLAS from Memorial Sloan Kettering Cancer Center and was discovered through research conducted in the laboratory of David A. Scheinberg. Although the REGAL findings provide clinical evidence supporting this approach, further detailed analyses will be important to understand the treatment’s full clinical profile and the characteristics of patients most likely to benefit.
Safety Findings and Planned FDA Regulatory Discussions
SELLAS reported that GPS was generally well tolerated, with a safety profile consistent with previous clinical experience and no new safety signals identified in the REGAL trial. Treatment-related adverse events were predominantly mild to moderate, classified as Grade 1 or Grade 2, with injection-site reactions among the most commonly reported events. The company also stated that the treatment groups were balanced for prognostic stratification factors and that the relatively small number of patients who proceeded to stem cell transplantation was distributed equally between the study arms. Following the positive topline results, SELLAS plans to meet with the U.S. Food and Drug Administration (FDA) to discuss a potential accelerated filing strategy. The company is advancing preparations for a Biologics License Application (BLA) submission, which it currently intends to pursue in the first half of 2027. Detailed statistical assessments of secondary endpoints and additional prespecified analyses are still underway. SELLAS expects to present comprehensive findings at a future major medical conference and submit the results for publication in a peer-reviewed journal. GPS remains investigational and has not received FDA approval. The regulatory outcome and the timing of any potential application will depend on further data review and discussions with the agency. The REGAL results nevertheless represent a significant development for SELLAS as it advances its WT1-targeted immunotherapy programme for patients with AML.
Source: SELLAS Life Sciences press release



